Maksymiak G.I.1, Shcheglovska T.D.1, Nikolayenko A.N.2, Коrnilina Е.М.2, Zhylchuk V.E.1, Zhylchuk A.V.1, Shcheglovskyj I.S.1, Philipchuk B.A.1

Aim: to study the effectiveness of the ERBISOL® ULTRApharm in the complex treatment of patients with disseminated non-small cell lung cancer (NSCLC). Object and methods: 84 patients with stage T2–4N1–3M1 NSCLC. All the patients received 6 palliative courses (at intervals 21 days) of chemotherapy (CT): gemcitabine (1000 mg/m2 on days 1 and 8); cisplatin (85 mg/m2 on 1 day). Patients in the experimental group received ERBISOL® ULTRApharm according to the appropriate scheme (course duration 19 days) in addition to each course of CT. Two months after completion of 6 courses of CT in combination with ERBISOL® ULTRApharm­, patients of the main group with partial regression or stabilization of the tumor process received two immunotherapy courses with ERBISOL® ULTRA­pharm. Patients in control and experimental groups with cancer disease progression received 4 courses of the second-line CT (each 3 weeks — paclitaxel 225 mg/m2 on day 1; carboplatin AUC 6, on day 1) after 2–3 months of the end of primary CT. In addition to the second-line CT, patients in the experimental group received ERBISOL® ULTRApharm according to the scheme similar to primary CT. Standard clinical, laboratory and instrumental methods of patient examination were used. The effectiveness of the drug was assessed by the level of the objective tumor response, the duration of the stabilization period, patient survival, characteristics of patients’ quality of life and the toxicity of CT. Results: the application of ERBISOL® ULTRApharm allowed to achieve a significant improvement in clinical symptoms and the indexes of clinical and biochemical examination and led to a decrease in the frequency of CT adverse reactions, an improvement of life quality (Karnowski index 66.3% vs 51.9% in the control group). Disease stabilization was registered in 57.1% patients in the experimental group and in 40.5% in the control group; partial regression was seen in 11.9% and 2.4% patients in the experimental and control groups respectively. Conclusions: the application of ERBISOL® ULTRApharm allowed to achieve a positive therapeutic effect in patients with NSCLC, namely, to reduce CT side effects, to improve life quality, to prolong disease stabilization, and to increase overall and 12-month survival. ERBISOL® ULTRApharm can enrich the arsenal of tools for nowadays immunotherapy of patients with malignant neoplasms.

No comments » Add comment